Global Pulmonary Arterial Hypertension Market Size

Global Pulmonary Arterial Hypertension Market Opportunities And Strategies 2023

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s pulmonary arterial hypertension market report forecasts the pulmonary arterial hypertension market size to grow to $10.47 Billion by 2027, with a CAGR (compound annual growth rate) of more than 8%.

Learn More On The Pulmonary Arterial Hypertension Market Report 2023 –

Pulmonary Arterial Hypertension Market Size Forecast
The global pulmonary arterial hypertension market is expected to grow from $7.05 billion in 2022 to $7.63 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pulmonary arterial hypertension market size is expected to grow to $10.47 billion in 2027 at a CAGR of 8.2%.

North America held the largest pulmonary arterial hypertension market share.

Key Pulmonary Arterial Hypertension Market Driver ­– Increase In The Prevalence Of Pulmonary Arterial Hypertension Disease
According to a National Organization for Rare Disorders, Inc. study, new cases of PAH are estimated to occur in one to two people per million in the United States each year, equating to 500-1000 new cases per year, with Europe expected to have similar incidence rates.

Request for A Sample Of The Global Pulmonary Arterial Hypertension Market Report:

Key Pulmonary Arterial Hypertension Market Trend – Technological Advancement
Pharmaceutical companies will focus on the development of new medicines to improve and cure pulmonary arterial hypertension. In April 2021, United Therapeutics Corporation, a biotechnology company based in the United States launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Tyvaso is an inhalation solution that helps patients improve their exercise abilities, reduce breathing problems, have a low tolerance for exertion, and have a higher mortality rate.

Pulmonary Arterial Hypertension Market Segment
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational
3) By Distribution channel: Retail, Online

Pulmonary Arterial Hypertension Market Major Players and Strategies
Major players in the pulmonary arterial hypertension market are United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc., Natco Pharma Ltd., Zydus Pharmaceutical USA, and Liquidia Technologies Inc.

Merck Group, a German-based multinational science and technology company specialising in healthcare and life sciences solutions, paid $11 billion for Acceleron Pharma in September 2021. Merck will gain ownership of Acceleron’s portfolio of rare disease therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication, and will be at the forefront of rare disease-focused companies as a result of this acquisition. Acceleron Pharma is a company based in the United States that is dedicated to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions like pulmonary arterial hypertension.

The Pulmonary Arterial Hypertension Global Market Report 2023 covers regional data on pulmonary arterial hypertension market size, pulmonary arterial hypertension market trends and drivers, opportunities, strategies, and pulmonary arterial hypertension market competitor analysis. The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Pulmonary arterial hypertension is a form of high blood pressure that affects both the right side of the heart and the arteries in the lungs. The artery walls of the lungs become constricted and rigid as a result of this long-term, incurable condition. The drugs used to treat pulmonary arterial hypertension either relax the muscles in the blood vessel walls, increase blood flow through the lungs, or reverse the effect of the substance in the blood vessel walls that causes the vessels to narrow.

View More Reports Related To The Pulmonary Arterial Hypertension Market –
Anticoagulants Global Market Report 2023
AntiHypertensive Drugs Global Market Report 2023
Bioabsorbable Stents Global Market Report 2023

Contact us at:
The Business Research Company:
+1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
Global Market Model:

Found this article helpful? Share it on: